Former Visiting Professor of Oncology and Scholar
Massachusetts General Hospital Cancer Center
Present phone & E-Mail address:
Mobile phone in Bosnia: +387 62 415 728
Augustus 12, 2016.
A Summary of Curriculum Vitae (CV) in 10 sentences
Dr. Mujagic is retired Visiting Professor and Scholar at Harvard University/ Massachusetts General Hospital and former Institutional Review Board Member for Harvard University Cancer Center, Boston and former Consultant for Xanthus Pharmaceuticals, Cambridge, Massachusetts, USA. He graduated from the University of Zagreb Medical School in 1968 where he also received his basic clinical training. He obtained his Masters degree from the University of Zagreb in 1973 and his PhD from the Universities of Essen, Germany and Zagreb in 1976. He received his specialty training in Internal medicine from several clinical centers in Europe and from the University Medical Center and Ministry of health in Sarajevo in 1980. He worked at Institute Rudjer Boskovic from 1969-1971 and Central Institute for tumors in Zagreb from 1971-1977, the National Cancer Institute of the USA in Bethesda from 1978-1979 and then from 1980-1984, at the Memorial Sloan-Kettering Cancer Center, New York, from 1984-1985, at the Universities in Banjaluka and Tuzla and as a Visiting Scholar and Professor at Harvard University and Massachusetts General Hospital from 2000 and on, where he has spent most of his last 12 professional years . He interchanges his residency between Boston and Bosnia but currently lives in Sweden and Bosnia. He is married with Dr. Amira Cehic a Swedish physician and overlakare specialized in child and adolescent psychiatry. He is specialist in Internal Medicine/subspecialties Urologic Oncology and Cancer Pharmacology and is Professor of Medicine and Oncology. He published 106 research papers, was or is on the Editorial Boards of 5 journals is reviewer for several prestigious scientific journals and is cited thus far 429 times around the globe, h-index=9, i10-index=9, RG score=23.10, RG impact=52.46. His areas of expertise are: Cancer Chemotherapy and Immunotherapy,Design and conduct of Clinical trials and Cancer drug analysis and writing.
After graduation from Medical faculty I did my internship at the University hospital “Sisters of Mercy” of the University in Zagreb. I started my professional career as a Fellow laureate of the Scientific Foundation of the Republic Croatia in 1969 as a Postgraduate assistant in the Institute of Natural Sciences “Rudjer Boskovic” at the University of Zagreb, Croatia. I was the first candidate selected by the Institute to be educated in translational research. I worked in the laboratory of tumor and transplantation immunology and at the University hospital Merkur. My primary responsibility was to organize and conduct the first clinical trial in Europe of specific immunotherapy in ovarian cancer patients. I prepared a vaccine consisting of irradiated ovarian cancer cells mixed with Freund’s adjuvant and injected patients with the vaccine subcutaneously three times at weekly intervals. I treated 35 patients and observed a delay in time to progression of disease and prolongation of survival length. Data from this work were not published. I finished there my postgraduate studies and prepared my Master of Sciences thesis elaborating a test of experimental pulmonary metastases in C57BL mice and graduated with summa cum laude from the Center for Advanced Studies at the University of Zagreb in 1972.
After almost two years I was invited to the newly organized Central Institute for Tumors and Allied Diseases in Zagreb and I established there a laboratory of Clinical tumor Immunology. I worked in that institution for seven years as a Clinical research assistant, Clinical associate and Head of Tumor immunology. My responsibilities were to organize clinical trials in the fields of Immunotherapy and Chemotherapy. I wrote several clinical research protocols, organized the first clinical trial of immunotherapy for malignant melanoma patients, a clinical trial of immunotherapy in ovarian cancer patients, and a trial of immunochemotherapy in bronchial cancer and soft tissue sarcoma patients. As immunotherapeutic agents I used BCG, Corynebacterium parvum and Lactobacillus acidophilus. I also introduced several investigative chemotherapy protocols especially in breast and lung cancer patients. During my work at the Central Institute in Zagreb, which served as the Central oncologic institute for Croatia, I went twice to the German Clinical Tumor Center at the University in Essen. There I started my PHD dissertation which I finished at my home institution in Zagreb. In Germany I was again engaged in clinical trials at surgical and medical clinics conducting clinical research in immunotesting of cancer patients. At that period I also spent several months working at the National Cancer Institute of Romania, Bucharest developing in vitro immunologic tests in cancer patients.
In 1978,after 15 years in Zagreb, I moved to the University Medical Center in Sarajevo, Bosnia, where I finished my residency and Board certification in Internal medicine. There I organized the Department of Clinical Oncology and Division of Chemotherapy and Immunotherapy and became the Head of the Department of Oncology. In collaboration with the Ministry of Health of Bosnia and the Physician Association of Bosnia I authored first clinical program in oncology and organized and conducted the country’s first clinical trials in chemotherapy for lung cancer patients. I also introduced standard chemotherapy protocols that at that time were in use in the United States and in Western Europe. In 1977 I wrote and introduced informed consents in clinical practice for the first time in South Europe.
In 1979 I was selected as International Union Against Cancer (UICC) Fellow for the first Course in Experimental Cancer Research in Europe. A year later as a recipient of International Cancer Research Technology Transfer Award (ICRETT) of UICC I worked at the National Cancer Institute in Bethesda in Laboratory of Immunodiagnosis being occupied with isolation and characterization of tumor-specific antigens. I shortly returned to the same institution in 1980 to work for another four years in the cell kinetics section of the Clinical Pharmacology Branch, Division of Cancer Treatment of the National Cancer Institute. Besides being engaged with cancer patients I primarily worked with cancer cell cytoskeleton models and I elaborated a test of cytoskeletal decoration with monoclonal anti tubulin antibodies that made it possible to visualize Vinca and other drug-induced cytoskeletal changes. I also elaborated a test showing rapid phenotypic changes in lymphoma cells in vitro. During that time at the NIH/NCI I discovered a new compartment in cell cycle-the cytoskeleton synthesis phase.
At the end of 1984 I accepted a highly competitive invitation and fellowship in Clinical Oncology from the Memorial Sloan-Kettering Cancer Center in New York. I spent one year and a half there working in the area of clinical trials. At Memorial I was responsible for the conduct of two clinical trials: The use of DETOX vaccine for intralesional immunotherapy of malignant melanoma patients and the use of IFN g in immunotherapy of kidney cancer patients. I also was involved in a clinical trial to treat hypercalcemia in breast cancer patients. In addition, together with Dr. Alan Houghton as the first in the world we prepared a monoclonal anti-melanoma antibody and I was honored as first physician to introduce one of first infusions to a melanoma patient. I was very excited with that trial since one could in fact see clinical manifestation of antibody effect (redness around melanoma nodules and shrinking of nodules). Unfortunately about 70% of antibodies showed a non-specific effect. I was also working with AIDS patients and was one of first to introduce interleukins and Detox vaccine in their treatment. I was also responsible for the treatment of Kaposi sarcoma patients with intratumoral injection of DETOX vaccine. It was at the Memorial where I first started to be deeply interested to monitor drug interactions and adverse drug reactions.
At the end of 1985. despite attempts of the USA Government which tried to prevent me from going back to Bosnia, I intentionally interrupted my career, left the USA forcefully and went to Bosnia. I wanted to take a part in defending my home country from Serbian and Croat aggressions. Since no one at the University medical Center in Sarajevo was willing to give me a job and actually at that time leading physicians in Sarajevo organized themselves in an elaborated plot to prevent me from being appointed at that center I was forced to go to Banjaluka. I organized Clinical Oncology services at the University Medical Center in Banjaluka including a 55 bed clinic and a day care hospital. I taught my associates in design and conduct of clinical trials and educated 12 physicians and 25 nurses specialized in the conduct of clinical trials in medical oncology. I established standard protocols and systems to monitor chemotherapy effects and side effects. Despite of fulfilling the criteria of a full Professor I was forced to start there as an assistant Professor and later was elected as the associate Professor of medicine. I established there a chair in Pathologic physiology and taught undergraduate medical students in Pathologic physiology and Internal medicine In years between 1986-1990 I also served as a Consultant for melanoma and skin tumors at the Clinic of plastic surgery of the University medical center in Sarajevo.
Because of the Serbian aggression on Bosnia, in the middle of 1993, from ethnic and confessional reasons, I was, under dramatic life threatening conditions, forced to leave the city of Banjaluka. I refused several invitations from my colleges from the USA to come back and, after being medically treated in Zagreb, a year later I settled in Tuzla, Bosnia.I still wanted to be engaged in defending my home country. As a world renowned physician I was again prohibited to get a job in Sarajevo and I spent a year trying to get a job at the Medical center in Tuzla. Somehow after many attempts I was appointed as an associate Professor of Pathologic physiology at the Medical faculty of the University of Tuzla.There I taught under-graduate and post-graduate students in Pathologic physiology and Medical Oncology and became a Head of Chair in Pathologic physiology and Head of Chair in Clinical Oncology. I lectured about design and conduct of clinical trials at the University. Later I was elected as a full Professor and appointed as a Professor of molecular medicine at the Postgraduate studies of the Medical faculty/University of Tuzla and after four years I also was elected as the Director of Postgraduate studies. In 1997 I was invited to assume a position as a Visiting Professor at the Department of Oncology of the University Hospital Marburg an der Lahn and I have spent my time there working on aggressive chemotherapy and bone marrow transplantation.
Since the year of 2000 and from there on I was privileged to be associated with Harvard University and Massachusetts General Hospital/Dana Farber/ Harvard Cancer Center upon several invitations from Dr. Bruce A. Chabner, and Dr.Donald Kaufman. Dr. Chabner was my former Director at the National Institutes of Health/National Cancer Institute, Bethesda. Maryland. At that time he was appointed as a Clinical Director of the MGH Cancer Center and I was privileged to help him to organize that Center serving several clinical and research positions as a Scholar, Clinical Research Scholar and Professor of Oncology and Scholar. In 2000 I was engaged mostly in a trial of a cell-based vaccine in prostate cancer patients at the Dana-Farber Cancer Center. In 2003 I wrote a chapter about thalidomide and was engaged in the area of aggressive chemotherapy and bone marrow transplantation in patients with hematologic malignancies. In 2005 I served as a Ribakof Fellow in genitourinary oncology, and became responsible for revising systems monitoring adverse drug reactions in Dana-Farber/MGH trials. Most of 2006 I spent working on drug safety and pharmacovigilance for Harvard Cancer Center. In November of 2006 I was appointed as a Consultant for hematologic malignancies for Xanthus Pharmaceuticals, Cambridge. I was especially engaged in developing oral formulation of fludarabine monophosphate and in work with chronic lymphocytic leukemia and myelodysplastic syndromes. I prepared IND and NDA as well as orphan drug applications for fludarabine monophosphate in chronic lymphocytic leukemia. I completed a series of 5 didactic courses at the MGH in the area of clinical trials or closely related to clinical trials.
Skill oriented CV
This part of my CV documents knowledge in clinical experience, management and analytical skills in Clinical trials, drug analysis and reporting, writing and editing of medical texts, and safety and FDA regulatory drug procedures.
What I do best
1. I am best at taking care of cancer patients
2. Design, monitoring and reporting of Clinical trials.
3. Medical drug analysis and writing
4. Drug safety, pharmacovigilance and reporting
4. Writing and editing of medical texts.
1. Knowledge and experience in Clinical Research Methodology, Protocol and Study design and Medical terminology and Administration accumulated at Massachusetts General Hospital/Harvard University and Xanthus Pharmaceuticals, Boston and Cambridge, Memorial Sloan-Kettering Cancer Center, New York, NY and National cancer Institute, Bethesda, Maryland.
2. Over 18 years of clinical experience in managing, monitoring, analyzing and reporting results of anticancer drug therapeutic trials within University Hospitals and other Academic Institutions outside Contracts with Biopharmaceutical Companies.
3. Special experience in gastrointestinal, lung and breast oncology, and malignant melanoma Oncology.
4. Monitoring and procedures with Clinical Research Protocols, Member of Dana Farber/Harvard University Cancer Center Institutional Review Board, Boston.
5. Six years of research laboratory experience in cell culture, cell kinetics drug research, and cancer immunology.,
6. Industrial and scientific drug research, analysis and reporting.
7. FDA regulatory procedures (bioequivalence, non-inferiority, 505 b 2, etc.).
8. Clinical development of fludarabine monophosphate (2F-ara-AMP) first line and second line in patients with CLL for Xanthus Pharmaceuticals, Cambridge.
9. Special experience in Adverse Drug Reactions, Drug Interactions, and Drug Safety and Reporting-2 years of experience at Harvard University Cancer Center.
10. Knowledge of rules and regulations about protection of human research subjects (CITI exam passed 2 years ago).
11. Strong organizational, interpersonal and communication skills, and good management skills with attentions to details, and hidden pitfalls.
07/2005-present Boston, USA
Massachusetts General Hospital Harvard University, Visiting Professor, Scholar, and Ribakof Fellow.
Fellowship in Genitourinary Oncology, The Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital, Boston.
Revision of systems and protocols monitoring adverse drug reactions for Dana-Farber/Harvard Cancer Center, Boston.
Assist in clinical monitoring of subjects for Phase I-III Clinical Research Studies within departments of Genitourinary Oncology and Medical Gynecology at the Massachusetts General Hospital Cancer Center.
Analysis and reporting data about “carcinoma in situ” of breast cancer Patients.
Active participation in four Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center Clinical Research Courses:
1. Design and Conduct of Clinical Trials.
2. Statistical Methods for Clinical Investigators.
3. Tumor measurements.
4. CITI Program and Exam for Protection of Research Subjects.
07/2003-12/2003. Boston, USA
Massachusetts General Hospital Harvard University, Visiting Scholar, and Clinical Research Fellow.
Participation in the following Clinical trials at The Dana-Farber/Harvard Cancer Center:
1. A phase I trial of PT523 in patients with solid tumors.
2. PS 341 in patients with solid malignancies.
3. CP868596 Dose escalation Study to evaluate Safety.
Review of data about dose intensity and dose density distributions of chemotherapy in elderly cancer patients.
Writing papers about thalidomide and its metabolites.
11/2000-3/2001. Boston, USA
Massachusetts General Hospital Harvard University, Visiting Scholar and Clinical Research Fellow In Medicine.
Participation in Clinical Trials of aggressive chemotherapy and bone marrow transplantation.
01-06/1997. Marburg, Germany
University Clinic, Department of Oncology/Hematology/Immunology Philips University Marburg. Visiting Professor.
Active participation in Clinical Trials of aggressive chemotherapy and bone marrow transplantation in patients with hematologic malignancies.
Consulting in chemotherapy and hormonal therapy of patients with solid tumor malignancies.
06/1994-07/2005. Tuzla, Tesanj, Gracanica, Bosnia
University of Tuzla, Professor and Head of Oncology. Tesanj General Hospital, Gracanica General Hospital.
Planning, designing and developing of clinical protocols, and Investigator Brochures.
Negotiating contracts with other investigators.
Analysis and interpretation of Clinical data and reporting end results.
Acting as a medical liaison between investigators and organizations.
Organized and led investigators and contractors meetings.
Clinical work with patients enrolled in actual Clinical Trials.
Teach and train undergraduate students, doctors and nurses about design and conduct of Clinical Trials in Oncology.
07/1985-07/ 1992 Banjaluka, Bosnia
University of Banjaluka Associate Professor and Head of Clinical Oncology Services.
Initiation, organization, monitoring and managing phase I-IV Clinical Trials in Oncology.
Actual clinical work with cancer patients.
Organization of pre-study, site initiation and investigator meetings.
Organized and led investigators and contractors general meetings.
Review Clinical Trials submitted from other institutions.
Supervised clinical monitoring, evaluations and site visits.
Assisted in grant proposals, study protocols, and publications.
Taught students, fellows, researchers, pharmaceutical representatives and nurses in design and conduct of Clinical trials.
07/1984-07/ 1985 New York, NY, USA
The Memorial Sloan-Kettering Cancer Center/Cornell University, New York. Fellow in Oncology.
Active participation in Clinical trials and taking care of cancer patients.
1. Intralesional non-specific immunotherapy with “Detox” vaccine in malignant melanoma patients.
2. Immunotherapy with Interferon gamma in kidney cancer patients.
3. Managing hyperphosphatemia in breast cancer patients. Teaching residents in Immunotherapy Trials.
01/1980-07/ 1984 Bethesda, Maryland , USA
National Institutes of Health,
National Cancer Institute,
Clinical Pharmacology Branch.
Visiting Scientist and Consultant
Clinical Research work in Cancer pharmacology and Immunology.
1. Discovering the effects of Vinca alkaloids on cell skeleton and discovering the new compartment in cell cycle..
2. Phenotypic changes in myeloma cells in vitro.
3. Drug resistance/sensitivity of breast cancer cells in vitro.
4. Cell culture, immunologic techniques, and drug research techniques.
07/1977-12/ 1980 Sarajevo, Bosnia
University Medical Center.
Head of the department Of Oncology,
Consultant in Oncology,
Head melanoma and Skin cancer unit.
Design, organization and conduct of a clinical trial of non-specific immunotherapy in malignant melanoma patients.
Taught undergraduate and graduate students in “Methods and Conducts of Clinical trials” .
Design and conduct of chemotherapy trials in lung cancer patients.
Taking care of cancer patients.
Initiated study specific training of clinical investigators.
Collaborated closely with Bosnian and Croatian pharmaceutical industry in developing criteria and procedures about monitoring drug adverse reactions and reporting about drug safety.
01/1972-07/ 1977 Zagreb, Croatia
The Central Institute for tumors and Allied Diseases.
Clinical Research Scientist and Head of Tumor Immunology
Authored and executed the first Clinical trial of BCG Immunotherapy in malignant melanoma patients.
Developed study protocols, developed study-related materials including case report forms, deviation from protocols, etc.
Participated in development of chemotherapy protocols for patients with solid malignancies.
Helped the hospital management in negotiations with the Pharmaceutical industry and the Scientific Foundation of the Republic of Croatia.
Participated in the identification and recruitment of investigators including travel inside and outside the former Yugoslavia.
Assisted in the development of patient recruitment strategies, advertising using electronic media, and collaboration with pharmaceutical companies.
Monitored and co-monitored (as needed) the accuracy of interim report torms, and case report forms to ensure that they are accurate against original patients data and other verifiable sources.
Track and provide data essential to status of ongoing studies.
Prepared for and led project team meetings and provided update of project performance.
Developed guidelines and training manuals.
Introduced Clinical Immunotherapy methods and immunological techniques in vitro.
Development of skin testing protocols with the German Clinical tumor center, University of Essen and Central Institute for tumors
01/1970-07/ 1972 Zagreb, Croatia The Institute of Natural Sciences “Rudjer Boskovic”.
Education (experimental and clinical combined) in translational research as a first candidate in former Yugoslavia.
Developed and executed Clinical Trial of active specific immunotherapy in ovarian cancer patients.
Irradiated tumor cells and prepared vaccines individually for each patient.
2005-2006 Fellowship in Genitourinary Oncology, Clinical Trials, Adverse drug reactions and safety. Massachusetts General Hospital/Harvard University, Boston, MA.USA.
2003-2004 Clinical trials with anti-tumor vaccines. Drug writing and reporting. Massachusetts General Hospital/Dana-Farber Cancer Institute/Harvard University, Boston MA.USA.
2000-2001 Clinical trials in aggressive chemotherapy and bone marrow transplantation. Drug writing and reporting. Massachusetts General Hospital/Harvard University, Boston MA.USA.
1987-1988 Clinical trial in aggressive chemotherapy and bone marrow transplantation. University Hospital, Marburg, Germany.
1984-1985 Fellowship in Medical Oncology, Clinical trials in melanoma and kidney cancer immunotherapy. Clinical trial in hyperphosphatemia in breast cancer patients. The Memorial Sloan-Kettering Cancer Center, New York , NY. USA.
1980-1984 Cancer pharmacology and laboratory research. Diagnostic trial in drug resistance. The National Institutes of Health, National Cancer Institute, Clinical Pharmacology Branch, Bethesda, Maryland.USA.
1982 ECFMG exam (equal to USMLE, Educational Commission For Foreign Medical Graduates, Philadelphia. PA, USA.
1984 FMGEMS clinical exam (Foreign Medical Graduate Examination in Medical Science). Educational Commission For Foreign Medical Graduates, Philadelphia. PA,USA.
1979 Immunologic research methods. National Institutes of Health, National Cancer Institute, Laboratory of Immunodiagnosis, Bethesda, Maryland, USA.
1974 Clinical Cancer Research Course. The Swiss Institute for Cancer Research, Lausanne, Switzerland.
1974 Cancer Radiobiology. Rumanian National Cancer Institute, Bucharest, Romania.
1973-1974 Residency in Medical and Surgical Oncology. German Clinical Tumor Center, University of Essen, Germany.
1977-1980 Residency in Internal Medicine. University Medical Center Sarajevo, Bosnia.
1972-1976 Clinical Associate. The Central Institute for Tumors And Allied Diseases, Zagreb, Croatia.
1972-1975 Doctor of Sciences and Philosophy. University of Essen, Germany, University of Zagreb, Croatia.
1969-1972 Master of Sciences, Center for Advanced Studies, University of Zagreb, Croatia.
1968-1969 Internship, University Hospital “Sisters of Mercy”, Zagreb, Croatia.
1963-1968 Doctor of Medicine, Medical Faculty University of Zagreb, Croatia.
Brief Chronology of Employment:
1968-1969 Internship, University Hospital “Sisters of Mercy” Zagreb, Croatia.
1969-1970 Physician in commissioned Military Service.
197O-1971 Postgraduate Research Assistant in Oncology, Institute
“Rudjer Boskovic ”University of Zagreb, Croatia.
1971-1975 Clinical Research Assistant and Scientist, Head of Tumor
Immunology Group, The Central Institute for Tumors, and A
llied Diseases, Zagreb, Croatia.
1975-1977 Clinical Research Associate, Head of Tumor Immunology,
The Central Institute for Tumors and Allied Diseases, Zagreb, Croatia.
1971-1977 Clinical Associate, Department of Medical Oncology and
Chemotherapy, The Central Institute for Tumors and Allied
Diseases, Zagreb, Croatia.
1977-1978 Head, Division of Chemotherapy and Immunotherapy,
The Institute of Radiology and Oncology, University Medical
Center Sarajevo, Bosnia. Associate Head and Professor,
Postgraduate Studies from Experimental and Clinical Oncology,
Medical Faculty University of Sarajevo, Bosnia.
1978-1980 Head, Department of Oncology, Consultant in Oncology,
The University Medical center Sarajevo, Bosnia. Head of Malignant
Melanoma and Skin Tumors Unit in the Clinic for Plastic and
Reconstructive Surgery, University Medical Center Sarajevo, Bosnia.
198O-1985 Visiting Scientist, Clinical Oncology Program, Division of Cancer
Treatment, National Cancer Institute, National Institutes of Health,
1984-1985 Clinical Fellow in Oncology, The Memorial Sloan-Kettering
Hospital for Cancer and Allied Diseases, New York, NY.
Consultant for Drug Resistance, Division of cancer Treatment
National Cancer Institute, Bethesda, USA.
1985-1986 Head of Malignant Melanoma and Skin Tumors Unit, The
Clinic for Plastic and Reconstructive Surgery, University
Medical Center Sarajevo, Bosnia.
1986-1991 Head of Oncology, The Clinical and University Hospital
Center Banjaluka, Bosnia.
1987-1990 Assistant Professor of Pathologic Physiology, Head of Chair
and Institute of Pathologic Physiology, Medical faculty
University of Banjaluka, Bosnia.
1987-1991 Head of Melanoma Unit, The Clinic for Plastic and Reconstructive
Surgery, University Medical Center Sarajevo, Bosnia.
1990-1992 Associate Professor of Medicine and Oncology, Medical
faculty University of Banjaluka, Bosnia.
Director of Clinical Oncology, University Hospital Center
1992-1994 Interruption in Career because of War activities in Bosnia.
1994 Professor of Pathologic Physiology, Medical Faculty University
of Tuzla, Bosnia. Professor of Molecular Oncology at
Postgraduate Studies, Medical faculty University of Tuzla,
Bosnia, Consultant in Oncology.
1997 Professor and Chair in Clinical Oncology, Medical faculty
University of Tuzla, Bosnia and Herzegovina.
Professor of Pathologic Physiology and Professor of Molecular
Oncology at the Postgraduate Study Course, Medical faculty
University of Tuzla. Consultant, Ministry of Health of Kanton Tuzla.
1998 Visiting Professor of Oncology, Ludwig Maximilian University,
2000 Visiting Scholar and Research Fellow in Medicine, Harvard University
Massachusetts General hospital, Boston, USA.
2001-2003 Director of Postgraduate Studies, Medical faculty, University of Tuzla
2003-2004 Visiting Professor of Oncology and Scholar, Harvard University,
Massachusetts General Hospital, Boston, USA.
2003-2007 Visiting Professor of Oncology and Hematology, Harvard University,
Massachusetts General Hospital.
2007- Visiting Professor of Oncology/Hematology and Scholar, Harvard
University, Massachusetts General Hospital, Boston, USA. Ribakof
Fellow in Oncology, Member of the Committee for Clinical Trials,
Dana Farber/Harvard Cancer Center, Boston, USA.
International Diplomas and Certificates:
Massachusetts General Hospital and Harvard University, Ribakof Fellowship in Genitourinary Oncology, Diploma.
Massachusetts General Hospital and Harvard University, Design and Conduct of Clinical Trials, Certificate.
Massachusetts General Hospital and Harvard University, Statistical Methods for Clinical Investigators, Certificate.
Massachusetts General Hospital/University of Miami, ICTI-Program for Protection of Research Subjects, Certificate.
Dana-Farber Cancer Institute and Harvard University, Tumor Measurements, Certificate.
ECFMG, Educational Committee for Foreign Medical Graduates, Philadelphia, Pennsylvania , USA, Diploma.
FMGEMS, Foreign Medical Graduates Examination in Medical Sciences, Certificate of Clinical Part.
National Institutes of Health, National Cancer Institute, Diploma.
Division of Cancer Treatment, National Cancer Institute, Certificate.
American Society of Clinical Oncology, Diploma.
World Health Organization Geneve, Certificate.
International Union Against Cancer, Certificate.
Principal Investigator of Research Projects:
Served thus far as principal investigator of 12 Research Projects from the
Fields of Biomedical Sciences, and Oncology in USA, Croatia, and Bosnia.
Collaboration in Research Projects:
Closely collaborated in 7 Research Projects.
Number of publications: 106.
1. International books: 1 in press, middle of 2013.
2. Chapters in international books: 7.
3. Books: 7.
4. Papers in peer review journals: 49.
5. Papers published in Congress books or summaries: 43.
Knowledge of Languages:
- English and German (talks fluently, reads and writes).
- Franch, Italian and Russian (reads and understands).
- Speaks and understands several Balkan languages and dialects.
Board Certified Specialties:
Urologic Oncology, Harvard University/Massachusetts General Hospital, Boston, USA. Internal Medicine, The Ministry of Health of the Republic of Bosnia, Yugoslavia.
1. Drug analysis and writing.
2. The design and conduct of phase I-III Clinical trials.
3. New anticancer drugs and adverse reactions.
- Phases I-III Controlled Clinical Trials.
- Oncogenetic diagnostics and therapy.
- Oncogenomics and Pharmacogenomics.
Membership in Editorial or Advisory Boards:
- Former Associate Editor, Acta Medica Saliniana.
- Regional Editor, Croatian Medical Journal.
- Former Member of the Editorial Board of “The Oncologist”, USA.
- Member of the Editorial Board of Libri Oncologici, Zagreb, Croatia.
- Member of the Editorial Board of Journal od Clinical and Biological Research, South Africa.
Retired as Professor of Oncology and Scholar, Harvard University, Massachusetts General Hospital, Boston, MA, USA.
Microsoft Word, Microsoft Publishing, Adobe programs, SPSS, Statistica, MiniTab, Sigmastat, Outlook, Clinical Trials, E-trials portal, Excel, etc.
List of Publications:
Selected publications can be found in following databases:
Entrez PubMed, www.ncbi.nlm.nih.gov/entrez (type in Mujagic H)
Science Citation Index Expanded, www.portal.isiknowledge.com (type in Mujagic H).
Biosis, www.gateway.ut.ovid.com , (type in Mujagic H).
EMBASE, www. embase.com
The National Library of Medicine of the USA: www.nlm.nih.gov
The Francis A Countway Library of Medicine, Hatvard Medical School, www.countway.harvard.edu
A. International Books:
Hamza Mujagic, Editor, Immunology, The University of Sarajevo, Planned for the middle of 2014.
B.Chapters in international books
1. Anuj Mahindra, Hamza Mujagic, Bruce A. Chabner: Immunomodulatory drugs and proteasome inhibitors, in: Harrison’s Manual Of Oncology, editors; BA Chabner and DL Longo, The McGraw Hill Co. 2014, pages 72-83.
2. Bruce A. Chabner, Jeffrey Barnes, Joel Neal, Hamza Mujagic, Lecia Sequist, Wyndham Wilson, and Dan L. Longo: Chapter 62
Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal antibodies, and Cytokines, in: Goodman and Gillman, The Pharmacological Basis of Therapeutics, McGraw-Hill Co.,2010. pages:1731-1754
3. Mujagic Hamza: Thalidomide and its analogs, in: Harrisons Manual of Oncology, Editors: B A Chabner, D L Longo and T Lynch, The McGraw Hill Co. 2007.
4. Mujagic Hamza and Bruce A Chabner: The Taxanes. In: Harrisons Manual of Oncology, Editors: B A Chabner, DL Longo and T Lynch, The McGraw Hill Co, 2007.
5. Supko GJ, Puchalski AT, Mujagic H, Zhu AX, Chabner BA. Clinical Pharmacology of Anticancer Drugs. Handin RI, Lux SE, Stossel TP, eds. Handin’s Textbook of Hematology. Lippincott Williams & Wilkins, 2002: 2095-2133.
6. Curt GA, Allegra CJ, Fine RL, Mujagić H, Yeh GC, Chabner BA. Cancer Chemotherapy. Ulmann’s Encyclopedia of Chemistry. VCH
Verlagsgesellschaft, 1986; A5: 1-28.
7. Silobrčić V, Milas L, Mujagić H. Experimental lung metastases as a test in tumour immunology. Doll R, Vodopija I, eds. Host environmental interactions in the ethyology of cancer in man. WHO IARC, 1972: 411-417.
1.Zlata Mujagic, Hamza Mujagic: Biochemistry of Drugs,University of Tuzla,2012.
2. Zlata Mujagic, Hamza Mujagic: Biohemstry of cellular transduction signals, University of Tuzla,2012.
3. Mujagić H. Practical Pathologic Physiology, University of Banjaluka 1987.
4. Mujagić H. Selected chapters from Pathologic Physiology, University of Banjaluka 1988.
5. Nurkić M, Mujagić H. Immunological dictionary, University of Tuzla 2001.
6. Mujagić H, Radovanović Z, Cuculić M, Vujanović N, Vujić A, Čobić P. The acquired immunodeficiency syndrome-AIDS: Svjetlost- Sarajevo, 1988.
7. Mujagić Hamza, Mujagić Zlata: Agressiveness of tumor disease, Hamidovic, Tuzla, 2003.
C. Peer-review publications
1. Hamza Mujagic. Systems Biology: Potential to Improve Decision Making in Pharmaceutical Development. Drug News & Perspect 2006, 19(9): 575-579.
2. Mujagić H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE. Effects of Vincristine on Cell Survival, Cell Cycle Progression, and Mitotic Accumulation in asynchronously growing Sarcoma 180 Cells. Cancer Res 1983; 43: 3591-3597.
3. Mujagić H, Conger BM, Smith CE, Occipinti SJ, Shuette WH, Schackney SE. Schedule dependence of Vincristine lethality in sarcoma 180 cells following partial synchronisation with Hydroxiurea. Cancer Res 1983; 43: 3598-3603.
4. Milas L, Mujagic H. Protection by Corynebacterium parvum against tumor cells injected intravenously. Europ J Clin Biol Res 1972; 17: 498-500.
5. Milas L, Mujagić H. The effect of splenectomy on fibrosarcoma metastases in lungs of mice. Int J Cancer 1973; 11: 186-190.
6. Mujagić H, Chabner BA, Mujagić Z. The mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J. 2002; 43(3): 274-285.
7. Mujagić H, Shackney CE, Smith CE, Chen SS. Quantitative changes in surface immunoglobulin expression in WEHI-231 lymphoma cells in relation to their proliferative rate. Oncology, 1986; 43: 237-242.
8. Mujagić H, Kolarić K, Malenica B, Nola P. BCG immunotherapy in previously treated malignant melanoma patients. Biomedicine, 1979; 30: 95-102.
9. Mujagić H. Immunotherapy with BCG: an attempt at standardization of methods based on our experience and results. Period Biol 1980; 82(2): 195-205.
10. Mujagić H, Krnjajić N, Jevrić A. The levels and relations of prostaglandins in pregnant and non-pregnant tumor-bearing mice. J Cancer Res Clin Oncol 1989; 115: 383-387.
11. Mujagić H, Mujagić Z. Detection of pleyotropic drug resistance by the rapid immunofluorescence assay of drug effects on cell skeleton. Oncology 1991; 48(3): 202-209.
12. Mažuran R, Mujagić H, Malenica B, Silobrčić V. In vitro detection of cellular immunity to melanoma antigens in men by the monocyte spreading inhibition test. Int J Cancer 1976; 17: 14-20.
13. Shuette WH, Chen SS, Occipinti SJ, Mujagić H, Shackney SE. Automated radioautographyc grain counting: correction for grain overlap. Cell Tissue Kinet 1983; 16: 221-227.
14. Mujagić Z, Mujagić H. Circulating levels of prolactin as an indicator of effectiveness of therapy in breast cancer patients. Int J Cancer 2002; Suppl 13: 216.
15. Mujagić Z, Mujagić H. Prolactin-new tumor marker for breast cancer? Turk J Biochem 2003; 28 (3): 120-121.
16. Mujagic Z, Mujagic H. Importance of serum prolactin determinations in metastatic breast cancer patients. Croat Med J. 2004; 45(2): 176-180.
17. Mujagic Z, Mujagic H. The relationship of circulating prolactin levels to the size of primary tumor in breast cancer patients. Turk J Biochem. 2004; 29 (4): 277-281.
18. Pranjic N, Mujagic H. Gasoline sniffing and lead toxicity in workers at gasoline stations. J Occup Env Med. 1998; 40(11): 1024-1029
19. Mujagić H, Krušić J, Dešković M, Malenica B. Immunological reactivity to non-specific antigens in cervical carcinoma patients. Period Biol 1976; 78:151-153.
20. Mujagić H, Nola P, Malenica B, Maričić Ž, Allegretti N. Immunological reactivity in colorectal carcinoma patients with special reference to the new classification of carcinomas of colon and rectum. Period Biol 1976; 78: 153-155.
21. Mujagić H, Mažuran R, Malenica B, Silobrčić V. Clinical detection of cellular immunity to melanoma-specific antigens in men by the monocyte spreading inhibition test: correlation between in vivo and in vitro immunological test parameters. Period Biol 1976; 78: 156-157.
22. Rogan J, Mujagić H, Malenica B. Lymphocyte cytotoxicity to malignant melanoma and cervical carcinoma cells. Period Biol 1976; 78: 155-156.
23. Malenica B, Mujagić H, Kolarić K, Radetić M, Maričić Ž, Roguljić A, Rogan J, Vukas D. BCG immunotherapy in metatsatic malignant melanoma. Period Biol 1976; 78: 158-159.
24. Mujagić H.The chemotherapy of gastric carcinoma. The Medical Herald 1978;14:71-76.
25. Mujagić H, Dešković M, Malenica B, Bistrović M, Krušić J. The significance of tuberculin immunity testing in cancer patients (invited article). Cell Molec Biol 1980; 26: (2):111-123.
26. Malenica B, Mujagić H, Popović S, Eljuga D, Allegretti N, Rogan-Grgas J. Immunocompetence in patients with malignant melanoma. Period Biol 1983; 16: 351-353.
27. Krnjajić N, Jevrić A, Krnjajić Z, Filipović I, Mujagić, H. Comparison of PGE and PGE2 levels in pregnant syngeneic Balb/c mice with transplanted fibrosarcoma. Prog Clin Res 1987; 242: 119-122.
28. Mujagić H. Aggressive chemotherapy and sensitivity persistance to anticancer drugs. Ann. Paul Debre Hosp 1990; 41: 7-15.
29. Mujagić H, Blitvić A, Omeragić F. I can see you but you can not see me. Cancer Updates 1999; 1(3): 4 -11.
30. Mujagic H, Chabner BA. Thalidomide. MD Vista J Med 2001; 4: 1-7.
31. Mujagić H, Malenica B, Nola P, Maričić Ž, Kolarić K. BCG immunotherapy applied after surgery in malignant melanoma patients. The Med Rev, Galenika 1976; 16: 42-48.
32. Mujagić H, Roth A, Smudj K, Malenica B, Juzbašić S. Immunotherapy and chemotherapy in the treatment of advanced osteosarcoma-A case report. Iugosl Orthopaed Acta 1977; 2: 209-213.
33. Mujagić H. The possibilities of immunotherapy of malignant tumors in men. Med Arch 1978; 32: 43-49.
34. Mujagić H. The monitoring of lymphocyte blast specific and non-specific transformation in malignant melanoma patients and the possibilities of clinical utilisation of results. Radiol Jugosl 1978; 12: 794-804.
35. Krnjajić N, Jevrić A, Petronijević S, Krnjajić Z, Mujagić H. PGE2 levels in pregnant syngeneic BaLb/c mice with transplanted methylcholanthrene induced fibrosarcoma. Iugoslav Physiol Pharmacol Acta, 1985; 21 (3): 191-192.
36. Pertonijević S, Krnjaić N, Jevrić A, Mujagić H. PGF2 alfa levels in pregnant syngeneic BALB/c mice with transplanted methylcholantrene fibrosarcoma. Iugoslav Physiol Pharmacol Acta 1985; 21(suppl.3) p. 66.
37. Mujagić H. Morphological changes in cell skeleton caused by anticancer drugs. Informations about karcinogens 1990; 7: 9-23.
38. Pjanić A, Unčanin D, Sarajlić O, Abaspahić E, Mujagić H. Detection of cellular immunity in gastrointestinal carcinoma patients by the leucocyte adherence inhibition assay. Scripta Medica, 1991; 22: 10-16.
39. Šabanović Z, Mujagić H, Bazrdjanović M. Quality of medical records as a basis for DRG classification in the health care system in Bosnia and Hercegovina. Med Arch 1999; 53 (suppl 3): 61-64.
40. Ljuca Dž, Fatušić Z, Mujagić H, Ljuca F, Alispahić N. Precarcinoma and early carcinomatous lesions in the uterine cervix and the use of oral contraceptives. Med Arch 2000; 54 (2): 71-73.
41. Pranjić N, Mujagić H, Nurkić M, Karamehić J, Pavlović S. Assessment of health effects in workers at gasoline stations. Bosnian Journal of Basic Medical Sciences 2002, 2 (1-2): 35-45.
42. Pranjić N, Mujagić H, Pavlović S. Inhalation of gasoline and damage to health in workers at gasoline stations. Med Arch 2003; 57 (1): 17-20.
43. Mujagić H, Prnjavorac B, Mujagić Z, Festa G. Alcohol in alcoholic liver disease is a causative factor for development of allergic skin manifestations. Med Arch 2003; 57 (5-6): 273-278.
44. Mujagić Z, Mujagić H. Diagnostic usefulness of serum carcinoembryonic antigen determinations in breast cancer patients. Bosnian Journal of Basic Medical Sciences 2003; 3 (2): 30-34.
45. Mujagić Z, Mujagić H, Prnjavorac B. Circulating levels of prolactin in breast cancer patients. Med Arch 2005;59 (1):33-35.
46. Mujagić Z, Mujagić H, Prnjavorac B. The relationship between carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients. Med Arch 2004;58 (1): 23-26.
47. Mujagić Z, Mujagić H, Prnjavorac B. The relationship between circulating carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients. Med Arch 2004; 58 (1): 23-26
48. Zlata Mujagić, Nahida Srabović, Hamza Mujagic.The role of prolactin in human breast cancer. Biochemia Medica 2009;19(3):236-49.
49. Mujagić Z, Mujagić H. The sensitivity and Specificity of Prolactin (PRL) in Breas Cancer Patients. Acta Informatica Medica 2005; 13(4): 189-191.
D. International congresses and symposia publications
1. Mujagić H, Kolarić K. The value of immunological skin tests in Oncology. Book of abstracts of the Sec Int Cong Bulgarian Oncol, Varna, 1970. p.104.
2. Mažuran R, Mujagić H, Silobrčić V. Cellular immunity in vitro to melanoma-specific antigens in men detected by the macrophage spreading inhibition test. Book of abstracts of the 3th Europ Immunol Meeting, Amsterdam, 1975. p. 125.
3. Mujagić H, Milas L, Allegretti N, Nola P, Malenica B, Maričić Ž. Immunological reactivity in colorectal carcinoma patients with special reference to the new T-S classification of carcinomas on the colon and rectum. Book of abstracts of the Tenth Int Congr Gastroenter, Budapest, 1976. p. 412.
4. Mujagić H, Dešković M, Malenica B. Tuberculin immunity in cancer patients; clinical and prognostic significance. Bok of abstracts of the 12th Int Cancer Congr, Buenos Aires, 1978. p. 126.
5. Mujagić H, Kolarić K, Nola P. Immunological status in malignant melanoma patients. Book of abstracts of the 12th Int Cancer Congr, Buenos Aires, 1978. p. 188.
6. Mujagić H. Clinical immunological status in malignant melanoma patients. Book of abstracts of the 6th Europ Immunol Meeting, Paris, 1980. p. 188.
7. Mujagić H, Smith CE, Shuette WH, Shackney SE. The cell tubulin content frequency histogram obtained by flow cytometry in sarcoma 180 cells in vitro. Proc Am Assoc Cancer Res, Denver, 1982. p. 105.
8. Chen SS, Occipinti SJ, Mujagić H, Smith CE, Shuette WH, Shackney SE. Multiparameter radiographic image abalysis studies in human lymphomas Proc Am Assoc Clin Oncol, Denver, 1982. p. 107.
9. Conger B, Occipinti SJ, Mujagić H, Smith CE, Shuette WH, Shackney SE. Studies on lethal and sublethal effects of Vincristine on sarcoma 180 cells in vitro. Proc Am Soc Cell Kin, Houston, 1982. p. 32.
10. Radičević N, Mujagić H. The effect of methylnitrosourea (MNU) on the growth of transplanted methylcholanthrene-induced fibrosarcoma in Balb/c mice. Book of abstracts of the Second World Congress of Pharmacology, Tokyo, 1982. p. 103.
11. Radičević N, Mujagić H. The relationship of macrophage spreading inhibition (MSI) with tumor growth and non-specific immunotherapy. Book of abstracts of the 2th World Cong Pharmacol, Tokyo, 1982: Abs.10.5.56.
12. Mujagić H. Tumor-directed immune reactivity in malignant melanoma patients. Book of abstracts of the 2th World Congr Pharmacol, Tokyo, 1982: Abs.10.5.51.
13. Mujagić H, Smith CE, Occipinti S, Shuette WH, Shackney SE. The quantitative changes in immunoglobulin contents on the surface of WEHI231 lymphoma cells in relation to their proliferative rate. Proc Am Assoc Cancer Res, Atlanta, 1983. p. 32.
14. Curt GA, Bailey BD, Mujagić H, Chabner BA. Pleiotropic drug resistance in MCF-7 human breast carcinoma cell line. Proc Am Assoc Cancer Res, Houston, 1984. p. 104.
15. Petronijević S, Krnjajić N, Jevrić A, Mujagić H. PGF2 alfa levels in pregnant syngeneic Balb/c mice with transplanted methylcholanthrene fibrosarcoma. Joint Meeting Jugosl Finish Pharm, Dubrovnik, 1986. p. 66.
16. Krnjajić N, Petronijević S, Jevrić A, Krnjajić Z, Mujagić H. PGFalfa and PGF2alfa levels in pregnant syngeneic Balb/c mice with transplanted fibrosarcoma. Book of abstracts of the 6th Conf Prostagl Rel Comp, Florence, 1986. p. 206.
17. Krnjaić N, Jevrić A, Mujagić H, Krnjaić Z. The relationship between the levels of PGE1 and PGE2 and macrophage spreading inhibition in tumor bearing mice. 3th Int Symp Prostagland, Bad Ischly, 1986. p. 17.
18. Mujagić Z, Mujagić H. Diagnostic and Prognostic Usefulness of Prolactin (PRL) in Breast Cancer (BC). Proc. ASCO, San Francisco, 2001. p. 20 (43b).
19. Mujagić Z, Mujagić H. Prognostic significance of circulating levels of prolactin (PRL) in metastatic breast cancer (MBC). Proc ASCO, Chicago, 2003. p. 22(49).
20. Mujagic Z, Cicko E, Mujagic H. Circulating levels of prolactin before, during and after surgery in patients under total intravenous and general balanced anesthesia. Proceedings of IMMPC-2, Antalya, Turkey 2004.
21. Mujagic Z, Mujagic H. The relationship of circulating prolactin levels to the size of primary tumor in breast cancer patients. Proceedings of the 4th European Conference: «Perspectives in breast cancer», Madrid Spain 2004. p. 22. 22. Mujagić H, Milas L. The effect of Corynebacterium parvum on the growth of experimental metastases of fibrosarcoma in the lungs of C57BL mice. Proc Jugosl Immunol Soc, Beograd 1971. p.68. 23. Milas L, Mujagić H. The growth of experimental metastases of fibrosarcoma in the lungs of splenectomised C57BL mice. Proc Jugosl Immunol Soc, Beograd 1971. p. 67.
24. Mujagić H, Milas L, Malenica B, Jurčić D, Krušić J. Immunological reactivity in patients with rectal carcinoma. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 77.
25. Malenica B, Mujagić H, Radetić M, Maričić Ž, Roguljić A, Vukas D. BCG immunostimulation in malignant metastatic melanoma patients. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 30.
26. Mujagić H, Krušić J, Dešković M, Malenica B. Imunološka reaktivnost nespecifične antigene u bolesnica s karcinomom cerviksa. Book of abstracts of the Sixth Congr Jugosl Oncol,Sarajevo, 1975: 35.
27. Mujagić H, Mažuran R, Malenica B, Silobrčić V. Klinička detekcija celularne imunosti na melanomske antigene in vitro testom inhibicije širenja monocita. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 36.
28. Rogan J, Mujagić H, Malenica B. Citotoksičnost limfocita bolesnika s melanomom. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 49.
29. Mujagić H, Kolarić K, Malenica B, Popović Š, Maričić Ž. BCG- imunostimulacija bolesnika s malignim melanomom. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 80.
30. Mujagić H, Djordjević J, Lovrinčević A, Starović B. The extent of disease and frequency of localisation of metastases in malignant melanoma patients. Book of Abstracts of the Int Jugosl Radiol Congr, Novi Sad, 1980. p. 39.
31. Mujagić H, Malenica B, Nola P. Immunological Prophyle in malignant melanoma patients. Book of abstracts of the Sixth Int Cong Iugosl Oncol, Ljubljana, 1980. p.43.
32. Hadžiomerović V, Mujagić H, Bušić I. Immunological characteristics of patients with carcinomas of the head and neck. Book of abstracts of the Sec Int Congr ENT Soc, Niš, 1980. p. 21.
33. Hadžiomerović V, Mujagić H. The combination of Doxorubicin and radiotherapy in the treatment of patients with carcinoma of head and neck. Book of abstracts of the Sixth Int Congr Yugosl Oncol, Ljubljana, 1980. p. 44.
34. Krnjajić A, Jevrić A, Petronijević S, Mujagić H, Krnjajić Z. PGE2 levels in pregnant BaLb/c mice with transplanted methylcholanthrene Fibrosarcoma. Book of abstracts of the Ninth Congr Yugosl Pharm Soc, Beograd, 1985: p. 193.
35. Krnjaić N, Jevrić A, Mujagić H, Petronijević S, Krnjaić Z. PGE1 levels in pregnant syngeneic BALB/c mice with transplanted methylcholantrene fibrosarcoma. Book of abstracts of the 13th Congress of UYPS, Skopje, 1985: Abs. 291.
36. Mujagić H. Liječenje bolesnika sa malignim tumorom u uvjetima promijenjene ekološke sredine. Zbornik radova Simpozija o životnoj sredini, Novi Sad, 1990. p. 17.
37. Mujagić Z, Mujagić H. The relationship between smoking habits and serum prolactin levels in breast cancer patients. Proceedings of the First Bosnia and Herzegovina Congress of Occupational Medicine with International Participations, Tuzla, 2003. p. 242.
38. Mujagić Z, Mujagić H. Circulating levels of prolactin in relation to age in breast cancer patients. Proceedings of the First Bosnia and Herzegovina Congress of Occupational Medicine with International Participations, Tuzla, 2003. p. 256.
39. Mujagić Z, Mujagić H. Prolactin – new tumor marker for breast cancer? Turk J Biochem. 2003; 28 (3): 120-121.
40. Mujagić Z, Mujagić H. Diagnostic usefulness of serum carcinoembryonic antigen determinations in breast cancer patients. Bosnian Journal of Basic Medical Sciences 2003; III(2):30-34.
41. Mujagić Z, Mujagić H, Prnjavorac B. Circulating levels of prolactin in breast cancer patients. Med Arch 2005; 59(1): 33-35.
42. Mujagić H, Prnjavorac B, Mujagić Z, Festa G. Alcohol in alcoholic liver disease is causative factor for development of allergic skin manifestations. Med Arch 2003; 57(5-6), 273-278.
43. Mujagić Z, Mujagić H, Prnjavorac B. The relationship between circulating carcinoembryonic antigen (CEA) levels and parameters of primary tumour and metastases in breast cancer patients. Med Arch 2004; 58(1), 23-26.
Prof. dr.med. sc. Hamza Mujagic
Powered by ORBUS